Laboratorios Farmaceuticos Rovi

Historical price data

Laboratorios Farmaceuticos Rovi is a publicly-traded Spanish pharmaceutical company with a mission to develop, manufacture, and commercialize innovative therapies, particularly in biosimilars and low molecular weight heparins. The company has achieved significant scale through its dual business model, combining a profitable specialty pharma division with a strategic CDMO arm that serves third-party clients. Its strategy focuses on R&D investment in biosimilars as a core growth engine, while expanding its international commercial footprint and manufacturing capabilities to capitalize on high-value market opportunities.

Integrated expertise in Low Molecular Weight Heparin (LMWH) development and manufacturing, coupled with a growing biosimilar development platform focused on cell line development, process optimization, and advanced sterile fill-finish capabilities for prefilled syringes.

Rovi competes in biosimilars against large pharma (e.g., Sandoz, Pfizer) and specialized biosimilar firms. In LMWH/specialty pharma, it faces global anticoagulant leaders. Its CDMO division competes with large global players (e.g., Lonza) and regional manufacturers. Rovi's differentiation lies in its integrated model, deep LMWH expertise, and European commercial focus.